These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20549348)

  • 1. Pathologic progression of mammary carcinomas in a C3(1)/SV40 T/t-antigen transgenic rat model of human triple-negative and Her2-positive breast cancer.
    Hoenerhoff MJ; Shibata MA; Bode A; Green JE
    Transgenic Res; 2011 Apr; 20(2):247-59. PubMed ID: 20549348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.
    Green JE; Shibata MA; Yoshidome K; Liu ML; Jorcyk C; Anver MR; Wigginton J; Wiltrout R; Shibata E; Kaczmarczyk S; Wang W; Liu ZY; Calvo A; Couldrey C
    Oncogene; 2000 Feb; 19(8):1020-7. PubMed ID: 10713685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma.
    Shibata MA; Maroulakou IG; Jorcyk CL; Gold LG; Ward JM; Green JE
    Cancer Res; 1996 Jul; 56(13):2998-3003. PubMed ID: 8674054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
    Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
    J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
    Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R
    Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene.
    Maroulakou IG; Anver M; Garrett L; Green JE
    Proc Natl Acad Sci U S A; 1994 Nov; 91(23):11236-40. PubMed ID: 7972041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Preclinical Application of an Immunocompetent Transplant Model of Basal Breast Cancer with Lung, Liver and Brain Metastases.
    Aprelikova O; Tomlinson CC; Hoenerhoff M; Hixon JA; Durum SK; Qiu TH; He S; Burkett S; Liu ZY; Swanson SM; Green JE
    PLoS One; 2016; 11(5):e0155262. PubMed ID: 27171183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice.
    Meyer-Losic F; Newman SP; Day JM; Reed MJ; Kasprzyk PG; Purohit A; Foster PA
    PLoS One; 2013; 8(12):e80305. PubMed ID: 24324595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The C3(1)/SV40 T antigen transgenic mouse model of prostate and mammary cancer.
    Shibata MA; Jorcyk CL; Liu ML; Yoshidome K; Gold LG; Green JE
    Toxicol Pathol; 1998; 26(1):177-82. PubMed ID: 9502400
    [No Abstract]   [Full Text] [Related]  

  • 10. Development and characterization of a progressive series of mammary adenocarcinoma cell lines derived from the C3(1)/SV40 Large T-antigen transgenic mouse model.
    Holzer RG; MacDougall C; Cortright G; Atwood K; Green JE; Jorcyk CL
    Breast Cancer Res Treat; 2003 Jan; 77(1):65-76. PubMed ID: 12602905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transformation of enriched mammary cell populations with polyomavirus middle T antigen influences tumor subtype and metastatic potential.
    Drobysheva D; Smith BA; McDowell M; Guillen KP; Ekiz HA; Welm BE
    Breast Cancer Res; 2015 Oct; 17(1):132. PubMed ID: 26429062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.
    Chan SR; Vermi W; Luo J; Lucini L; Rickert C; Fowler AM; Lonardi S; Arthur C; Young LJ; Levy DE; Welch MJ; Cardiff RD; Schreiber RD
    Breast Cancer Res; 2012 Jan; 14(1):R16. PubMed ID: 22264274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth.
    Mao SPH; Park M; Cabrera RM; Christin JR; Karagiannis GS; Oktay MH; Zaiss DMW; Abrams SI; Guo W; Condeelis JS; Kenny PA; Segall JE
    Breast Cancer Res; 2018 Oct; 20(1):131. PubMed ID: 30367629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SV40 T/t-antigen induces premature mammary gland involution by apoptosis and selects for p53 missense mutation in mammary tumors.
    Tzeng YJ; Zimmermann C; Guhl E; Berg B; Avantaggiati ML; Graessmann A
    Oncogene; 1998 Apr; 16(16):2103-14. PubMed ID: 9572491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SV40 small t-antigen prevents mammary gland differentiation and induces breast cancer formation in transgenic mice; truncated large T-antigen molecules harboring the intact p53 and pRb binding region do not have this effect.
    Goetz F; Tzeng YJ; Guhl E; Merker J; Graessmann M; Graessmann A
    Oncogene; 2001 Apr; 20(18):2325-32. PubMed ID: 11402328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The uteroglobin promoter targets expression of the SV40 T antigen to a variety of secretory epithelial cells in transgenic mice.
    Sandmöller A; Halter R; Gómez-La-Hoz E; Gröne HJ; Suske G; Paul D; Beato M
    Oncogene; 1994 Oct; 9(10):2805-15. PubMed ID: 8084586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inducible and coupled expression of the polyomavirus middle T antigen and Cre recombinase in transgenic mice: an in vivo model for synthetic viability in mammary tumour progression.
    Rao T; Ranger JJ; Smith HW; Lam SH; Chodosh L; Muller WJ
    Breast Cancer Res; 2014 Jan; 16(1):R11. PubMed ID: 24457046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature.
    Franks SE; Campbell CI; Barnett EF; Siwicky MD; Livingstone J; Cory S; Moorehead RA
    Oncogene; 2012 Jul; 31(27):3298-309. PubMed ID: 22020329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage.
    Zhu M; Yi M; Kim CH; Deng C; Li Y; Medina D; Stephens RM; Green JE
    Genome Biol; 2011 Aug; 12(8):R77. PubMed ID: 21846369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.
    Deeb KK; Michalowska AM; Yoon CY; Krummey SM; Hoenerhoff MJ; Kavanaugh C; Li MC; Demayo FJ; Linnoila I; Deng CX; Lee EY; Medina D; Shih JH; Green JE
    Cancer Res; 2007 Sep; 67(17):8065-80. PubMed ID: 17804718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.